SEATTLE, WA -- (MARKET WIRE) -- May 24, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced that it has achieved its enrollment target of 120 patients in its ongoing Phase I/II clinical trial of tgAAC94. The study is designed to assess the safety and potential efficacy of different doses of tgAAC94 administered directly to affected joints of patients with inflammatory arthritis. tgAAC94 is an investigational therapy that utilizes an adeno-associated virus (AAV) vector to deliver the gene encoding a soluble form of the receptor for TNF-alpha (TNFR:Fc). The TNFR:Fc protein is a potent inhibitor of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation.
